Drovid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drovid

Property Description
Active Ingredient Ofloxacin
Form Oral Tablets, Ophthalmic Solution, Otic Solution
Pharmacological Class Fluoroquinolone Antibiotic (Second-Generation)
Common Use Treating a broad range of bacterial infections
Origin Synthetic

What Type of Medicine is Drovid and What is it Made Of?

Drovid is a prescription-only, synthetic antimicrobial agent whose active ingredient is Ofloxacin. This medication is classified as a powerful antibiotic belonging to the fluoroquinolone group, specifically categorized as a second-generation fluoroquinolone. Ofloxacin is chemically a racemic mixture, containing both the active isomer, levofloxacin, and the less active isomer, dextrofloxacin. As a single-component product, its synthetic origin distinguishes it from naturally derived antibiotics, marking its place in modern pharmaceutical development. The World Health Organization (WHO) includes Ofloxacin on its List of Essential Medicines, indicating its sustained importance in global public health treatment protocols.


How Does Drovid Function and What is Its General Purpose?

The general purpose of Drovid is to fight bacterial infections by eliminating the microorganisms responsible for the illness. Its high-level action is fundamentally bactericidal, meaning it actively kills the target bacteria rather than merely inhibiting their growth. Ofloxacin acts by interfering with the bacteria's core genetic processes, specifically by blocking key enzymes such as DNA gyrase and topoisomerase IV. This mechanism of action, characteristic of its class, interrupts DNA replication, thereby preventing the bacteria from multiplying and ensuring effective microbial clearance, which is critical in treating a wide spectrum of infections.


What Are the Available Forms of Ofloxacin?

Drovid (Ofloxacin) is available in multiple dosage forms suitable for both systemic and topical administration. For systemic infections, the medicine is provided as oral tablets, which, compared to some similar compounds, offers high oral bioavailability for effective body-wide distribution. For localized problems, the active substance is also formulated as a sterile liquid solution, specifically ophthalmic solutions (eye drops) and otic solutions (ear drops), allowing for direct, concentrated treatment of external tissues. The use of this single active agent across various routes of administration is a differentiating factor, allowing healthcare providers to rely on the consistent profile of Ofloxacin across different infection sites.

Regulatory References

  1. WHO Model Lists of Essential Medicines
  2. Ofloxacin - Essential Medicines List

What side effects are possible with Drovid?

Possible Side Effects and Safety Information

As a systemic fluoroquinolone antibiotic, Drovid (Ofloxacin) has an official safety profile categorized by potential adverse reactions across multiple body systems, organized by frequency and severity as documented by regulatory authorities (EMA/FDA).


Adverse Reaction Scope and Frequency

Adverse reactions are classified according to incidence. Uncommon effects include gastrointestinal issues (e.g., nausea, diarrhea) and Central Nervous System (CNS) effects (e.g., headache, dizziness, insomnia). Rare or Very Rare effects involve serious events impacting the Musculoskeletal and Nervous Systems.

System-Organ Class (SOC) Common/Uncommon Effects (Examples) Rare/Serious Adverse Reactions
Gastrointestinal Nausea, Diarrhea, Abdominal pain Clostridioides difficile-associated diarrhea (CDAD)
Nervous System Headache, Dizziness, Insomnia Peripheral neuropathy (potentially irreversible nerve damage), Seizures
Musculoskeletal Tendinitis and Tendon Rupture (e.g., Achilles tendon)
Cardiac/Vascular Tachycardia (Rare) Aortic aneurysm/dissection, Heart valve regurgitation, QT prolongation

Serious Adverse Reactions and Safety Patterns

The most significant safety elements documented in official labeling concern the risk of serious, disabling, and potentially irreversible side effects associated with systemic use. These include tendon rupture, symptoms of nerve damage (peripheral neuropathy), and major vascular events like aortic aneurysm and dissection. These reactions may occur rapidly, within the first 48 hours of treatment, and have been reported to manifest or persist months after stopping the medication.

Population-Specific Safety Considerations: Increased risk for tendon rupture and aortic events is noted for older adults and patients concurrently taking systemic corticosteroids. The drug is generally contraindicated in patients with a history of hypersensitivity to fluoroquinolones. Caution is also advised for patients with renal impairment or pre-existing QT interval prolongation risk factors.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile identifies specific systemic manifestations associated with Drovid (Ofloxacin) overdose. These documented presentations include central nervous system (CNS) effects such as drowsiness, dizziness, slurred speech, and confusion, alongside gastrointestinal symptoms like nausea and reports of hot and cold flushes. Overdose management should primarily address these CNS and gastrointestinal concerns.

Immediate medical help is required for any suspected overdose or for the first signs of severe, life-threatening outcomes, including convulsions (seizures), cardiovascular collapse, or severe allergic (anaphylactic) reactions.

Feature Official Regulatory Statement
Population-specific Overdose Note Overdose risk and severity may be increased in the elderly and those with impaired renal function due to reduced drug clearance.
Treatment Constraint No specific antidote is known; management is limited to symptomatic and supportive treatment.
Monitoring Requirement ECG monitoring is necessary to observe for QTc prolongation risk.

The regulatory guidance mandates that in the event of an overdose, appropriate supportive care must be instituted immediately. The profile further emphasizes that because the substance is not effectively removed by hemodialysis, the focus remains on intensive monitoring and supportive measures until documented manifestations resolve.

Therapeutic Uses of Drovid

What Drovid Treats: Main Uses and Benefits

Drovid is a medication applied in situations involving certain distressing symptoms across multiple areas. The core therapeutic approach is applied in contexts marked by increased discomfort related to bacterial activity, which helps patients cope more steadily with disruptive symptomatic periods and assists with maintaining functional stability.

The medication is commonly used for managing conditions presenting with bacterial manifestations, including acute or episodic infections of the urinary tract, lower respiratory tract, and skin and soft tissues, as well as localized conditions affecting the eye and ear. It is relevant in clinical settings where supportive symptom management is appropriate.

Drovid is relevant for easing symptom clusters that may become intense or disruptive, such as painful or burning urination, excessive phlegm and cough, and localized swelling or purulent discharge. It generally helps provide symptomatic support during acute or persistent episodes of heightened discomfort.


Quick Fact: Support for Symptoms of Inflammation and Discharge

Quick Fact: Support for Symptoms of Inflammation and Discharge

Drovid assists with maintaining functional stability during symptomatic periods by addressing conditions where redness, tenderness, or abnormal discharge interfere with routine activities.

Regulatory References

  1. NIH StatPearls Ofloxacin Overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Drovid?

Eligibility for Drovid (Ofloxacin) is formally defined by regulatory labeling based on age, pre-existing conditions, and physiological status.

Systemic use is contraindicated (prohibited) for individuals with a known hypersensitivity to Ofloxacin or any other fluoroquinolone, a history of myasthenia gravis, or a history of tendon disorders related to previous fluoroquinolone administration.

Systemic safety and efficacy have not been established in children and adolescents; therefore, systemic use is contraindicated in this population. Conversely, specific topical forms may be approved for children over six months. Systemic use is also generally not recommended or contraindicated for women who are pregnant or breastfeeding.

Conditional use applies to patients with impaired renal function (creatinine clearance le 50 mL/min), where the official label requires caution and a mandatory dosage adjustment. Caution is also required for older adults, patients with existing CNS disorders, and individuals with a history of organ transplant.

What should I know about interactions with other medicines?

Drovid Interactions with other medicines and products

Drovid (Ofloxacin) is subject to several officially documented interactions that alter its exposure or create pharmacodynamic risk. All interaction information is aligned with government regulatory documents.


Pharmacokinetic and Exposure-Altering Interactions

Mechanism / Class Interaction Effect Timing Rule
Multivalent Cations (e.g., in Antacids, Iron, Zinc) Significantly reduces oral absorption of Ofloxacin due to chelation [FDA Label]. Must be separated by 2 hours (before or after Ofloxacin) [MedlinePlus].
Agents that Reduce Clearance (e.g., Probenecid) Officially reported to decrease the total renal clearance of Ofloxacin, thereby increasing systemic exposure [SmPC]. No specific timing rule, but monitoring is necessary.

Pharmacodynamic and Risk-Reinforcing Interactions

Co-administration with specific drug classes is officially associated with additive or reinforced risks:

  • QTc Prolongation: Concurrent use of Ofloxacin with agents known to prolong the QT interval (e.g., Class IA and III antiarrhythmics) carries a documented additive risk for QTc prolongation [FDA Label].
  • Tendon Rupture Risk: The use of Ofloxacin alongside Corticosteroids is officially linked to an increased risk of tendinitis and tendon rupture, particularly in elderly patients [FDA Label].
  • CNS Stimulation: Co-administration with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Theophylline may increase the risk of central nervous system stimulation and convulsive seizures [SmPC].
  • Oral Anticoagulants: The effects of Warfarin and its derivatives may be enhanced when combined with Ofloxacin, requiring close monitoring of coagulation parameters [SmPC].

Note: The administration of Ofloxacin with food does not significantly affect total systemic exposure.

Mechanism of Action

Drovid (Ofloxacin) operates through a specific bactericidal mechanism focused entirely on the pathogen's genetic integrity. The core action is defined by a dual interference with the bacterial enzymes essential for DNA maintenance and replication.

Blocking Essential Bacterial Genetic Enzymes

The mechanism begins with Ofloxacin binding to and inhibiting two critical bacterial enzymes: DNA Gyrase and Topoisomerase IV. By stabilizing the complex between these enzymes and the bacterial DNA, the drug prevents the necessary steps of DNA unwinding and resealing. This molecular blockade causes Double-Strand DNA Breaks within the microorganism, leading to a failure of bacterial cell viability.

Halted Replication and Active Cell Death

The accumulation of genetic damage triggers a cascade that prevents the pathogen from completing its life cycle. The simultaneous inhibition of DNA unwinding for replication and chromosome separation for division effectively halts the bacterial multiplication pathway. This interference leads directly to the active death of the microorganism (a bactericidal outcome), functionally resulting in the cessation of growth and decrease in the overall population count.

Dosage and Administration Information

Drovid (Ofloxacin) is administered through three official routes: oral for systemic therapy, and topical solutions (0.3%) for ophthalmic (eye) and otic (ear) localized applications. The form used dictates the precise dosing and frequency.

For systemic use, oral tablets are typically prescribed in strengths ranging from 200 mg to 400 mg per dose. The standard schedule for most infections is twice daily (every 12 hours), establishing a common maximum daily dose of 800 mg. However, some specific acute conditions utilize a 400 mg single oral dose. Treatment duration is indication-dependent, ranging from three days up to six weeks for chronic infections; the overall course should not exceed two months.

Oral administration allows intake with or without food. A specific timing constraint mandates that the tablets must not be taken within two hours of products containing metal ions, such as antacids. A key procedural adjustment is required for patients with impaired renal function; a dosage reduction is necessary when creatinine clearance is ≤ 50 mL/min. While the oral form is contraindicated in growing adolescents, the topical solutions are approved for use in children (e.g., otic for children 6 months). Otic administration requires the solution to be warmed in the hand for one to two minutes prior to instillation.

Recent Clinical Evidence

Research Evidence / Overview of studies for Drovid (Ofloxacin)

This section provides a patient-friendly overview of the official research structure for Drovid, including the types of studies conducted and what the findings described, without offering clinical guidance or making claims about personal outcomes.


Evidence for Use in Systemic Infections (Urinary and Respiratory Tract)

Research exploring Drovid for systemic conditions, such as infections of the urinary tract and lower respiratory tract, primarily relies on Randomized Controlled Trials (RCTs) and systematic reviews from regulators and scientific bodies. Research examined outcomes related to how symptoms change over defined treatment periods.

Researchers examined specific outcomes, including the rate of achieving a predefined clinical endpoint (monitoring symptom evolution and outcomes related to physical discomfort) and the rate of measuring pathogen reduction (monitoring changes in bacterial presence). Reported findings described patterns related to measurements of pathogen reduction and short-term symptom evolution. However, resistance patterns can complicate the evidence landscape, as some trials noted that rapid development of resistance was associated with certain types of bacteria.


Evidence for Use in Localized External Infections (Eye and Ear)

Research for the topical (eye and ear drop) forms of Drovid was studied for localized uses using specialized short-term clinical trials. For eye infections, studies monitored outcomes related to physical discomfort and the time to reaching a clinical and microbiological endpoint. For ear infections, research examined outcomes related to resolution of ear discharge and outcomes related to inflammatory or irritative states were monitored. While studies report how symptoms evolved in the observed populations, evidence quality varies across studies, and comparative evidence is lacking against all other topical treatments.


Long-Term Studies and Durability of Effect

Evidence for Drovid primarily focuses on short-term research during the acute phases of infection. For most common indications, the follow-up durations were limited to the immediate period after treatment conclusion. Therefore, long-term outcomes remain uncertain and are not consistently characterized across all uses. Research is ongoing, but definitive data describing the durability of the effect and the rate of infection recurrence over many months or years after treatment are insufficient for many common uses.

Key Studies & References

  1. Ofloxacin (Systemic and Topical): Drug Information and Clinical Use Overview

Frequently Asked Questions (FAQ)

Common questions about Drovid (FAQ)

Q: Is Drovid considered a 'strong' or 'broad-spectrum' antibiotic?

A: Drovid (Ofloxacin) belongs to the fluoroquinolone class of antibiotics. According to regulatory documents, this class is generally recognized in medicine as having activity against a broad spectrum of bacteria. This classification suggests it is effective against a wide variety of bacterial types.

Q: Is Drovid the same as Ofloxacin, or is it just a brand name?

A: Drovid is a brand name used for the medicine. The official active ingredient is Ofloxacin, which is the drug's generic name. This information is confirmed in FDA product listings and MedlinePlus.

Q: Why are fluoroquinolone antibiotics like Drovid sometimes reserved for specific cases?

A: Regulatory bodies have placed specific restrictions on the use of systemic fluoroquinolones, including Drovid. This is primarily due to the risk of rare, serious, disabling, and potentially irreversible side effects. Official guidance suggests they may be reserved for cases where other approved treatment options are deemed unsuitable.

Q: What is the average time it takes to start feeling better after taking Drovid?

A: Official information indicates that Drovid reaches its maximum concentration in the bloodstream one to two hours after an oral dose. However, official labeling does not provide a specific time frame for when a patient can expect to feel symptomatically better. The timeline for symptom improvement can vary depending on the type and severity of the specific infection.

Q: How long does Drovid stay in your system after the last dose?

A: The main half-life of Ofloxacin is typically between four and seven hours. While the drug is mostly cleared from the bloodstream within a few days, it can be detectable for at least 108 hours (around 4.5 days) in bodily fluids such as urine, according to regulatory pharmacokinetic data.

Q: Is it normal to feel a bit dizzy or lightheaded when taking Drovid?

A: Official safety data lists dizziness as an uncommon side effect of Drovid. Lightheadedness is also a reported central nervous system side effect. If these feelings become severe or persistent, it is important to discuss them with a healthcare professional.

Q: Can Drovid cause stomach problems like severe diarrhea, even after finishing the pills?

A: Regulatory documents warn that severe diarrhea, known as Clostridioides difficile-associated diarrhea (CDAD), is a potential, serious side effect. This condition has been reported to occur with Drovid either during treatment or several weeks to months after the medication has been stopped.

Q: Are the potential side effects of Drovid permanent?

A: Official warnings state that Drovid is associated with side effects that may be long-lasting and potentially irreversible. These include nerve damage (peripheral neuropathy) and potential complications from tendon rupture.

Q: Is there a risk of tendon pain or rupture with Drovid, and what joints are most affected?

A: Yes, there is an official warning regarding the risk of tendinitis and tendon rupture with Drovid use. The affected tendons can include those in the Achilles (back of the ankle), shoulder, hand, or other sites, with the Achilles tendon being the most commonly affected.

Q: Should I avoid dairy products like milk or yogurt while taking Drovid?

A: Drovid absorption can be reduced by minerals, specifically multivalent cations. Official instructions indicate that, due to potential reduced absorption, the medicine should be separated by two hours from products containing multivalent minerals like the calcium found in dairy products.

Q: Does Drovid affect blood sugar levels, especially for people with diabetes?

A: Official warnings state that Drovid can cause changes in blood sugar, potentially leading to high blood sugar (hyperglycemia) or low blood sugar (hypoglycemia). These effects can be severe, especially for patients who have diabetes.

Q: Does Drovid make you more sensitive to the sun or cause a severe sunburn?

A: Official drug information confirms that Drovid can increase the skin's sensitivity to sunlight and ultraviolet (UV) light. Patients are often advised to take protective measures, such as minimizing unnecessary or prolonged sun exposure, while taking this medicine.

Q: What is the risk of Drovid causing changes in mood or confusion?

A: Drovid has been linked to a number of psychiatric reactions in official labeling. These can include anxiety, restlessness, and confusion, as well as depression. In rare cases, more serious changes in mood and behavior have been reported.

Q: Can Drovid affect my heart rhythm or cause palpitations?

A: Official warnings exist because Drovid carries an additive risk for a change in heart rhythm called QTc prolongation. While the term 'palpitations' is not explicitly listed, an adverse event of tachycardia (fast heart rate) is reported in safety information. Any change in heart rhythm should be discussed with a healthcare professional.

Q: Is Drovid safe to use for children or people under 18?

A: Systemic Drovid is not established as safe or effective for use in children and adolescents under 18 years of age. The restriction is primarily based on concerns regarding the potential for adverse effects on developing bone, joint, or tendon structures.

Q: Does Drovid interact with any common vitamins or mineral supplements?

A: Yes. Supplements that contain multivalent minerals like Iron, Calcium, Magnesium, or Zinc can significantly reduce the body's absorption of Drovid. These supplements should be taken at least two hours before or two hours after your Drovid dose.

Q: Is it okay to drive or operate machinery while taking Drovid?

A: Due to the potential for central nervous system side effects like dizziness or seizures, official guidance suggests that individuals should use caution or refrain from driving a car, operating machinery, or engaging in activities requiring full alertness until they know how Drovid may affect them.

Q: Can taking Drovid cause a yeast infection or thrush?

A: Yes, post-marketing reports for Ofloxacin include vaginal candidiasis (a common type of yeast infection). Like many broad-spectrum antibiotics, Drovid can alter the balance of natural bacteria, potentially allowing yeast to overgrow.

Q: Is it true that Drovid can sometimes affect the nerves in your hands and feet?

A: The official MedGuide states that Drovid may cause nerve damage (peripheral neuropathy). This can lead to symptoms like pain, burning, tingling, numbness, or weakness, especially in the hands, arms, legs, or feet.

Q: How does Drovid relate to other fluoroquinolones like Ciprofloxacin (Cipro)?

A: Drovid (Ofloxacin) is classified as a second-generation fluoroquinolone antibiotic. It belongs to the same family of medicines as Ciprofloxacin (Cipro). It is also known to be the active isomer of Levofloxacin.

Q: Why does Drovid sometimes have warnings related to the central nervous system (CNS)?

A: Warnings are in place because Drovid can affect the brain and nervous system. This may result in side effects such as seizures, tremors, dizziness, or other changes in a patient's mood or behavior. Caution is advised for patients with existing CNS disorders.

Q: How quickly does Drovid get absorbed into the body after taking a tablet?

A: According to pharmacokinetic data, the maximum concentration of Drovid in the bloodstream is typically reached one to two hours after a patient takes the oral tablet.

Q: What is the difference between Drovid tablets and the eye/ear drop version?

A: The Drovid tablets are used for systemic use, meaning they treat infections throughout the body. The drops are for topical use, providing localized treatment for infections in the eye or ear. The risks and warnings are generally more significant for the systemic tablets.

Q: Why is it important to finish the whole course of Drovid, even if symptoms improve?

A: Official patient information stresses that completing the full prescribed course is generally important to help prevent the return of the infection and potentially limit the development of drug-resistant bacteria.

Q: Is Drovid effective against E. coli bacteria?

A: Yes. Laboratory data and clinical information confirm that Ofloxacin (the active ingredient in Drovid) has proven antibacterial activity against many isolates of E. coli. This makes it a treatment option for infections caused by this specific bacteria.

Q: Is Drovid used to treat infections in the prostate?

A: Yes. According to the FDA product listing, systemic Ofloxacin is approved for the treatment of prostatitis (an infection in the prostate gland) that is caused by susceptible strains of bacteria.

Q: Can Drovid cause ringing in the ears (tinnitus)?

A: Yes. Tinnitus (ringing or buzzing in the ears) has been reported as an adverse event during the post-marketing experience with Ofloxacin, according to official safety documentation.

Q: How does age affect the risk of side effects from Drovid?

A: Official warnings specifically state that the risk of serious side effects, such as tendon problems and aortic events, is officially noted to be higher in older adults (typically those over 60 years of age). Caution is advised in this population.

Q: What should I do if I miss a scheduled dose of Drovid?

A: According to official patient instructions, if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid a double dose, and the patient should resume their regular schedule.

Q: Does Drovid show up on standard drug screenings?

A: Scientific literature reports that Drovid has been shown to cause false-positive results for certain drug classes on some initial urine screening tests due to cross-reactivity. This potential for cross-reactivity is a factor that may be discussed with the screening provider.

How should Drovid be stored and disposed of?

Storage and Protection Requirements

Drovid (Ofloxacin) must be stored strictly according to regulatory mandates to maintain its quality. The medicine must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C (86 F).

Mandatory Conditions Prohibited Environments
Store in a closed container Keep from freezing
Protect from heat, moisture, and direct light Do not keep outdated medicine

It is an official requirement that the product be stored securely and kept out of the reach of children.

Disposal Instructions

When Drovid is expired or no longer required, disposal must be managed to avoid misuse and environmental risk. Regulatory guidance advises consulting a healthcare professional for specific disposal methods, such as utilizing a drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container before discarding it in the household trash. The labeling on the empty packaging must have all identifying information removed prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drovid found in:

A-Z Index: